MPR spoke with Dr Daniela Carvalho, an investigator in the CHORD trial, the results form which formed the basis for the approval of Otarmeni.

HealthDay News — For adults with prediabetes, a reduction in the risk for diabetes is seen after supplementation with 4000 IU/day of vitamin D 3 among those carrying the AC and CC alleles of the Apal ...

Rectal cancer is occurring earlier and killing younger adults faster, according to a study presented at Digestive Disease Week 2026, held from May 2 to 5 in Chi ...

Difference in total body weight loss between the treatment and control groups widened with time postintervention.

Phase 3 trial results demonstrate that bepirovirsen significantly increases the proportion of patients achieving functional cure compared with placebo.

The SYNCHRONIZE-1 trial evaluated survodutide in non-diabetic adults with obesity or overweight with at least 1 weight-related complication.

Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.

Phase 3 ReSPECT trial data show rezafungin is noninferior to standard antimicrobial regimens for the prophylaxis of invasive fungal diseases in HSCT patients.